TWA
CBIO

TCI Wealth Advisors’s Crescent Biopharma CBIO Stock Holding History

TCI Wealth Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1
Closed – – 1589
2019
Q3 		$0 Hold
1
– – ﹤0.01% 1537
2019
Q2 		$1K Hold
1
– – ﹤0.01% 1202
2019
Q1 		$1K Sell
1
-1
-50% -$1.15K ﹤0.01% 1219
2018
Q4 		$2K Hold
2
– – ﹤0.01% 997
2018
Q3 		$3K Sell
2
-2
-50% -$3.02K ﹤0.01% 916
2018
Q2 		$6K Buy
4
+1
+33% +$1.72K ﹤0.01% 733
2018
Q1 		$5K Buy
+3
New +$6.24K ﹤0.01% 732

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

TCI Wealth Advisors's CBIO Position: Q4 2019 in Review

TCI Wealth Advisors sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 1 share.

TCI Wealth Advisors first reported a position in CBIO in Q1 2018 and held it in 7 quarters. The position peaked at $6K in Q2 2018. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

  • TCI Wealth Advisors reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
  • TCI Wealth Advisors sold 1 Crescent Biopharma share in Q4 2019.
  • TCI Wealth Advisors first reported a position in Crescent Biopharma in Q1 2018 and held it in 7 quarters.
  • TCI Wealth Advisors's Crescent Biopharma position peaked at $6K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on TCI Wealth Advisors's 13F filing for Q4 2019, filed 27 Jan 2020.